{"id":"NCT00139737","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia","officialTitle":"Open Extension Study Evaluating the Safety and Tolerability of Oral Ziprasidone in the Treatment of Subjects Who Have Successfully Completed a Previous Ziprasidone Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-03","primaryCompletion":"2009-06","completion":"2009-06","firstPosted":"2005-08-31","resultsPosted":"2010-07-14","lastUpdate":"2021-03-03"},"enrollment":344,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Ziprasidone","otherNames":["Geodon, Zeldox"]}],"arms":[],"summary":"To provide treatment to eligible subjects who have successfully completed one of the following phase III ziprasidone studies, A1281028, A1281044, A1281045 (NCT00136994) or A1281088 (NCT00143351).","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Baseline up to 72 months","effectByArm":[{"arm":"Ziprasidone","deltaMin":177,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":17},"locations":{"siteCount":87,"countries":["Italy"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281061&StudyName=Extension%20Study%3A%20Evaluating%20the%20Safety%20of%20Oral%20Ziprasidone%20in%20the%20Treatment%20of%20Subjects%20with%20Schizophrenia"]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":331},"commonTop":["Electrocardiogram QT prolonged","Insomnia","Anxiety","Electrocardiogram abnormal","Headache"]}}